Notably, our in vivo experiments employed a PDCX model (31), which closely mimics the human tumor, providing a highly pertinent platform to evaluate the therapeutic potential of GITR-enhanced TILs in settings representative of human cancer. This evidence concerns the gene TNFRSF18 and neoplasm.